 Robert MacLaren
Concepts (494)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Critical Illness | 46 | 2025 | 857 | 6.660 |
Why?
| | Intensive Care Units | 41 | 2025 | 874 | 4.720 |
Why?
| | Critical Care | 25 | 2025 | 673 | 4.380 |
Why?
| | Peptic Ulcer | 9 | 2023 | 18 | 3.830 |
Why?
| | Gastrointestinal Hemorrhage | 8 | 2024 | 135 | 3.370 |
Why?
| | Hypnotics and Sedatives | 12 | 2024 | 217 | 3.150 |
Why?
| | Pharmacy Service, Hospital | 10 | 2024 | 84 | 3.070 |
Why?
| | Histamine H2 Antagonists | 9 | 2024 | 23 | 2.930 |
Why?
| | Pharmacists | 11 | 2025 | 258 | 2.800 |
Why?
| | Proton Pump Inhibitors | 9 | 2024 | 109 | 2.790 |
Why?
| | Enteral Nutrition | 13 | 2023 | 213 | 2.710 |
Why?
| | Dexmedetomidine | 9 | 2019 | 43 | 2.600 |
Why?
| | Gastric Emptying | 8 | 2017 | 37 | 1.880 |
Why?
| | Midazolam | 4 | 2024 | 72 | 1.550 |
Why?
| | Substance Withdrawal Syndrome | 5 | 2022 | 181 | 1.490 |
Why?
| | Shock, Septic | 4 | 2022 | 218 | 1.430 |
Why?
| | Epoprostenol | 2 | 2023 | 131 | 1.340 |
Why?
| | Anticoagulants | 12 | 2023 | 725 | 1.310 |
Why?
| | Heparin | 7 | 2023 | 254 | 1.290 |
Why?
| | Professional Role | 5 | 2024 | 167 | 1.180 |
Why?
| | Metoclopramide | 7 | 2010 | 19 | 1.180 |
Why?
| | Vasopressins | 4 | 2022 | 60 | 1.110 |
Why?
| | Sepsis | 7 | 2023 | 634 | 1.050 |
Why?
| | Stress, Physiological | 5 | 2021 | 451 | 1.040 |
Why?
| | Lorazepam | 4 | 2014 | 25 | 1.030 |
Why?
| | Adult | 55 | 2025 | 39715 | 1.000 |
Why?
| | Pneumonia | 5 | 2022 | 643 | 0.980 |
Why?
| | Retrospective Studies | 39 | 2024 | 16626 | 0.960 |
Why?
| | Hemorrhage | 9 | 2021 | 798 | 0.960 |
Why?
| | Humans | 117 | 2025 | 142526 | 0.930 |
Why?
| | Factor VIIa | 5 | 2016 | 43 | 0.920 |
Why?
| | Visual Acuity | 4 | 2024 | 451 | 0.920 |
Why?
| | Vasoconstrictor Agents | 5 | 2023 | 137 | 0.890 |
Why?
| | Thrombelastography | 2 | 2023 | 175 | 0.890 |
Why?
| | Thromboembolism | 2 | 2020 | 126 | 0.890 |
Why?
| | Neurosurgical Procedures | 2 | 2024 | 204 | 0.880 |
Why?
| | Recombinant Proteins | 13 | 2023 | 1364 | 0.870 |
Why?
| | Gastrointestinal Agents | 5 | 2010 | 67 | 0.870 |
Why?
| | Proton Pumps | 2 | 2014 | 8 | 0.870 |
Why?
| | Propofol | 5 | 2019 | 88 | 0.850 |
Why?
| | Ulcer | 1 | 2023 | 34 | 0.800 |
Why?
| | Retinal Degeneration | 2 | 2020 | 39 | 0.790 |
Why?
| | Alcoholism | 2 | 2022 | 834 | 0.720 |
Why?
| | Blood Coagulation Factors | 3 | 2020 | 54 | 0.720 |
Why?
| | Hypotension | 2 | 2022 | 126 | 0.700 |
Why?
| | Hypothermia, Induced | 2 | 2013 | 92 | 0.690 |
Why?
| | Oseltamivir | 1 | 2021 | 14 | 0.680 |
Why?
| | Burns | 3 | 2018 | 357 | 0.680 |
Why?
| | Anti-Ulcer Agents | 3 | 2017 | 15 | 0.680 |
Why?
| | Analgesia | 2 | 2018 | 104 | 0.680 |
Why?
| | Rhodopsin | 1 | 2020 | 11 | 0.660 |
Why?
| | Stress, Psychological | 4 | 2024 | 1129 | 0.660 |
Why?
| | Retinal Rod Photoreceptor Cells | 1 | 2020 | 18 | 0.650 |
Why?
| | Dependovirus | 1 | 2020 | 76 | 0.620 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2022 | 240 | 0.620 |
Why?
| | Vision Tests | 1 | 2019 | 20 | 0.610 |
Why?
| | Vision, Low | 1 | 2019 | 17 | 0.610 |
Why?
| | Venous Thromboembolism | 2 | 2021 | 337 | 0.600 |
Why?
| | Esomeprazole | 1 | 2018 | 7 | 0.590 |
Why?
| | Genetic Vectors | 1 | 2020 | 338 | 0.580 |
Why?
| | Middle Aged | 43 | 2025 | 35049 | 0.580 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2023 | 349 | 0.580 |
Why?
| | Fibrinolytic Agents | 3 | 2016 | 287 | 0.570 |
Why?
| | Fluid Therapy | 3 | 2023 | 143 | 0.570 |
Why?
| | Pulmonary Embolism | 1 | 2021 | 239 | 0.570 |
Why?
| | Acute Kidney Injury | 4 | 2023 | 829 | 0.560 |
Why?
| | Staphylococcal Infections | 1 | 2022 | 395 | 0.560 |
Why?
| | Genetic Therapy | 1 | 2020 | 315 | 0.550 |
Why?
| | APACHE | 3 | 2010 | 64 | 0.550 |
Why?
| | Phenytoin | 1 | 2017 | 21 | 0.550 |
Why?
| | Erythromycin | 4 | 2010 | 20 | 0.540 |
Why?
| | Albumins | 1 | 2017 | 112 | 0.520 |
Why?
| | Blood Coagulation Disorders | 2 | 2016 | 190 | 0.510 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 2 | 2015 | 24 | 0.510 |
Why?
| | Ethanol | 3 | 2022 | 637 | 0.510 |
Why?
| | Ketamine | 1 | 2018 | 127 | 0.510 |
Why?
| | Male | 53 | 2025 | 70910 | 0.500 |
Why?
| | Plasma | 2 | 2016 | 222 | 0.500 |
Why?
| | Anticonvulsants | 2 | 2017 | 227 | 0.470 |
Why?
| | Blood Coagulation | 2 | 2007 | 269 | 0.450 |
Why?
| | Glial Cell Line-Derived Neurotrophic Factor | 1 | 2015 | 18 | 0.450 |
Why?
| | Partial Thromboplastin Time | 4 | 2023 | 52 | 0.450 |
Why?
| | Hydrocortisone | 1 | 2017 | 310 | 0.450 |
Why?
| | Acetaminophen | 5 | 2010 | 263 | 0.450 |
Why?
| | Female | 50 | 2025 | 76624 | 0.450 |
Why?
| | Nitric Oxide | 1 | 2020 | 896 | 0.450 |
Why?
| | Nerve Growth Factor | 1 | 2015 | 34 | 0.450 |
Why?
| | Aged | 28 | 2024 | 25117 | 0.440 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 2014 | 28 | 0.440 |
Why?
| | Community-Acquired Infections | 2 | 2014 | 178 | 0.430 |
Why?
| | Influenza, Human | 1 | 2021 | 635 | 0.430 |
Why?
| | Stomach Diseases | 2 | 2011 | 20 | 0.430 |
Why?
| | Evidence-Based Medicine | 4 | 2024 | 721 | 0.420 |
Why?
| | Epinephrine | 1 | 2015 | 148 | 0.420 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2015 | 142 | 0.410 |
Why?
| | Antifibrinolytic Agents | 2 | 2007 | 59 | 0.410 |
Why?
| | Erythropoietin | 2 | 2005 | 98 | 0.410 |
Why?
| | Prospective Studies | 15 | 2025 | 7862 | 0.410 |
Why?
| | Polyvinyl Chloride | 1 | 2013 | 12 | 0.410 |
Why?
| | Voriconazole | 3 | 2019 | 22 | 0.390 |
Why?
| | Randomized Controlled Trials as Topic | 7 | 2023 | 1642 | 0.390 |
Why?
| | Hemodynamics | 2 | 2019 | 1114 | 0.390 |
Why?
| | Hippocampus | 1 | 2018 | 944 | 0.390 |
Why?
| | Pain | 1 | 2018 | 781 | 0.380 |
Why?
| | Sodium Chloride | 1 | 2013 | 141 | 0.380 |
Why?
| | Drug Monitoring | 3 | 2017 | 396 | 0.360 |
Why?
| | Mental Recall | 1 | 2013 | 212 | 0.360 |
Why?
| | Drug Resistance | 2 | 2011 | 151 | 0.360 |
Why?
| | Cross Infection | 4 | 2008 | 260 | 0.360 |
Why?
| | Gastrointestinal Hormones | 1 | 2011 | 5 | 0.350 |
Why?
| | Ghrelin | 1 | 2011 | 36 | 0.350 |
Why?
| | Hirudins | 4 | 2023 | 52 | 0.350 |
Why?
| | Double-Blind Method | 7 | 2020 | 2007 | 0.350 |
Why?
| | Pseudomonas Infections | 4 | 2010 | 225 | 0.350 |
Why?
| | Heparin, Low-Molecular-Weight | 2 | 2023 | 38 | 0.340 |
Why?
| | Cisapride | 2 | 2001 | 5 | 0.340 |
Why?
| | Neuromuscular Blocking Agents | 1 | 2011 | 25 | 0.340 |
Why?
| | Cohort Studies | 8 | 2023 | 5858 | 0.330 |
Why?
| | Gastrointestinal Microbiome | 1 | 2018 | 727 | 0.330 |
Why?
| | Neuromuscular Blockade | 1 | 2011 | 47 | 0.330 |
Why?
| | Coagulants | 2 | 2008 | 21 | 0.330 |
Why?
| | Factor VII | 2 | 2007 | 25 | 0.330 |
Why?
| | Infusions, Intravenous | 6 | 2016 | 421 | 0.330 |
Why?
| | Analgesics, Non-Narcotic | 2 | 2010 | 126 | 0.320 |
Why?
| | Pharmaceutical Vehicles | 1 | 2009 | 12 | 0.320 |
Why?
| | Factor Xa | 2 | 2021 | 35 | 0.320 |
Why?
| | Tachyphylaxis | 1 | 2009 | 5 | 0.320 |
Why?
| | Propylene Glycol | 1 | 2009 | 9 | 0.320 |
Why?
| | Drug Therapy, Combination | 6 | 2017 | 1053 | 0.310 |
Why?
| | Antiemetics | 3 | 2010 | 49 | 0.310 |
Why?
| | Protein C | 1 | 2010 | 54 | 0.310 |
Why?
| | Diabetic Retinopathy | 2 | 2024 | 206 | 0.310 |
Why?
| | Mutation | 2 | 2020 | 4024 | 0.300 |
Why?
| | Surveys and Questionnaires | 8 | 2020 | 5994 | 0.300 |
Why?
| | Extravasation of Diagnostic and Therapeutic Materials | 2 | 2023 | 20 | 0.300 |
Why?
| | Factor Xa Inhibitors | 2 | 2023 | 188 | 0.300 |
Why?
| | Heart Arrest | 1 | 2013 | 398 | 0.300 |
Why?
| | Treatment Outcome | 14 | 2024 | 11298 | 0.300 |
Why?
| | Pseudomonas aeruginosa | 4 | 2010 | 359 | 0.300 |
Why?
| | International Normalized Ratio | 2 | 2016 | 50 | 0.290 |
Why?
| | Bradycardia | 3 | 2021 | 52 | 0.290 |
Why?
| | Hemofiltration | 3 | 2017 | 23 | 0.290 |
Why?
| | Respiration, Artificial | 6 | 2019 | 694 | 0.290 |
Why?
| | Central Serous Chorioretinopathy | 2 | 2020 | 4 | 0.280 |
Why?
| | Immune System | 1 | 2009 | 183 | 0.280 |
Why?
| | Lung Diseases | 2 | 2007 | 786 | 0.280 |
Why?
| | Attitude of Health Personnel | 2 | 2014 | 1194 | 0.280 |
Why?
| | Drug Resistance, Multiple, Bacterial | 3 | 2005 | 78 | 0.280 |
Why?
| | Antifungal Agents | 3 | 2019 | 147 | 0.270 |
Why?
| | Photochemotherapy | 2 | 2020 | 39 | 0.270 |
Why?
| | Nursing Audit | 1 | 2007 | 4 | 0.270 |
Why?
| | Chromatography, High Pressure Liquid | 2 | 2024 | 590 | 0.270 |
Why?
| | Forms and Records Control | 1 | 2007 | 20 | 0.270 |
Why?
| | Peptide Fragments | 3 | 2023 | 697 | 0.270 |
Why?
| | Triazoles | 2 | 2019 | 166 | 0.260 |
Why?
| | Hemostatics | 1 | 2007 | 60 | 0.260 |
Why?
| | Physicians | 2 | 2013 | 937 | 0.250 |
Why?
| | Risk Management | 1 | 2007 | 91 | 0.250 |
Why?
| | Tandem Mass Spectrometry | 2 | 2024 | 566 | 0.250 |
Why?
| | Hydrogen-Ion Concentration | 5 | 2014 | 552 | 0.250 |
Why?
| | Bacterial Infections | 1 | 2008 | 245 | 0.250 |
Why?
| | Dopamine Antagonists | 2 | 2008 | 25 | 0.250 |
Why?
| | Clinical Pharmacy Information Systems | 1 | 2006 | 6 | 0.250 |
Why?
| | Glutamine | 1 | 2007 | 108 | 0.250 |
Why?
| | Respiration | 1 | 2007 | 209 | 0.240 |
Why?
| | Models, Economic | 1 | 2006 | 61 | 0.240 |
Why?
| | Anti-Bacterial Agents | 5 | 2022 | 1881 | 0.240 |
Why?
| | Factor VII Deficiency | 1 | 2005 | 3 | 0.240 |
Why?
| | Anesthesia | 1 | 2009 | 250 | 0.240 |
Why?
| | Anesthetics | 1 | 2007 | 98 | 0.240 |
Why?
| | Fentanyl | 3 | 2018 | 125 | 0.230 |
Why?
| | Intubation, Gastrointestinal | 2 | 2008 | 78 | 0.230 |
Why?
| | Practice Patterns, Physicians' | 1 | 2014 | 1353 | 0.230 |
Why?
| | Common Data Elements | 1 | 2025 | 14 | 0.230 |
Why?
| | Risk Factors | 9 | 2023 | 10593 | 0.220 |
Why?
| | Analgesics, Opioid | 3 | 2018 | 1123 | 0.220 |
Why?
| | Intravitreal Injections | 1 | 2024 | 61 | 0.220 |
Why?
| | Aged, 80 and over | 9 | 2024 | 8020 | 0.210 |
Why?
| | Macular Edema | 1 | 2024 | 47 | 0.210 |
Why?
| | Drug Interactions | 2 | 2023 | 404 | 0.210 |
Why?
| | Antidotes | 2 | 2016 | 148 | 0.210 |
Why?
| | Regression Analysis | 3 | 2017 | 1013 | 0.200 |
Why?
| | Anemia | 1 | 2005 | 175 | 0.200 |
Why?
| | Time Factors | 10 | 2018 | 7006 | 0.200 |
Why?
| | Patients' Rooms | 1 | 2022 | 13 | 0.200 |
Why?
| | Clostridium Infections | 2 | 2014 | 74 | 0.200 |
Why?
| | Delphi Technique | 1 | 2025 | 320 | 0.200 |
Why?
| | Saline Solution, Hypertonic | 1 | 2023 | 41 | 0.200 |
Why?
| | Cross-Over Studies | 3 | 2020 | 580 | 0.190 |
Why?
| | Angiogenesis Inhibitors | 1 | 2024 | 230 | 0.190 |
Why?
| | Erythrocyte Transfusion | 1 | 2005 | 209 | 0.190 |
Why?
| | Biological Availability | 1 | 2023 | 137 | 0.190 |
Why?
| | Microbial Sensitivity Tests | 3 | 2018 | 373 | 0.190 |
Why?
| | Warfarin | 2 | 2007 | 168 | 0.180 |
Why?
| | Predictive Value of Tests | 3 | 2017 | 2081 | 0.180 |
Why?
| | Antacids | 1 | 2001 | 16 | 0.180 |
Why?
| | Myocardial Infarction | 1 | 2009 | 1067 | 0.180 |
Why?
| | Renal Replacement Therapy | 2 | 2015 | 93 | 0.180 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2024 | 547 | 0.180 |
Why?
| | Minnesota | 1 | 2022 | 171 | 0.180 |
Why?
| | Colorado | 7 | 2017 | 4638 | 0.180 |
Why?
| | United States | 8 | 2024 | 15447 | 0.180 |
Why?
| | Anti-Infective Agents | 1 | 2004 | 243 | 0.170 |
Why?
| | Norepinephrine | 1 | 2022 | 191 | 0.170 |
Why?
| | Health Care Costs | 1 | 2005 | 422 | 0.170 |
Why?
| | Vitamin K 1 | 1 | 2001 | 3 | 0.170 |
Why?
| | Prothrombin | 1 | 2021 | 27 | 0.170 |
Why?
| | Stomach Ulcer | 2 | 2019 | 15 | 0.170 |
Why?
| | Pharmaceutical Preparations | 1 | 2023 | 172 | 0.170 |
Why?
| | Disseminated Intravascular Coagulation | 1 | 2001 | 32 | 0.170 |
Why?
| | Incidence | 3 | 2022 | 2826 | 0.170 |
Why?
| | Statistics, Nonparametric | 3 | 2016 | 432 | 0.170 |
Why?
| | Catheters | 1 | 2021 | 74 | 0.170 |
Why?
| | Decision Support Techniques | 3 | 2014 | 437 | 0.160 |
Why?
| | Light Coagulation | 1 | 2020 | 10 | 0.160 |
Why?
| | Gene Knock-In Techniques | 1 | 2020 | 60 | 0.160 |
Why?
| | Resuscitation | 1 | 2023 | 298 | 0.160 |
Why?
| | Length of Stay | 4 | 2014 | 1273 | 0.160 |
Why?
| | Inflammation | 1 | 2011 | 2867 | 0.160 |
Why?
| | Retinitis Pigmentosa | 1 | 2019 | 21 | 0.160 |
Why?
| | Area Under Curve | 3 | 2014 | 326 | 0.160 |
Why?
| | Thrombolytic Therapy | 1 | 2021 | 156 | 0.160 |
Why?
| | Ischemia | 1 | 2023 | 416 | 0.150 |
Why?
| | Photosensitizing Agents | 2 | 2020 | 43 | 0.150 |
Why?
| | Invasive Fungal Infections | 1 | 2019 | 11 | 0.150 |
Why?
| | Refraction, Ocular | 1 | 2019 | 43 | 0.150 |
Why?
| | Enzyme Inhibitors | 1 | 2002 | 837 | 0.150 |
Why?
| | Adrenal Cortex Hormones | 1 | 2002 | 502 | 0.150 |
Why?
| | Retinal Pigment Epithelium | 1 | 2019 | 79 | 0.150 |
Why?
| | Biometry | 1 | 2019 | 70 | 0.150 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2019 | 83 | 0.150 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2014 | 2053 | 0.150 |
Why?
| | Electric Stimulation Therapy | 1 | 2019 | 81 | 0.150 |
Why?
| | Disease Models, Animal | 2 | 2020 | 4483 | 0.150 |
Why?
| | Restraint, Physical | 1 | 2018 | 73 | 0.150 |
Why?
| | Administration, Inhalation | 1 | 2020 | 596 | 0.140 |
Why?
| | Patient Care | 1 | 2019 | 121 | 0.140 |
Why?
| | Stem Cell Transplantation | 1 | 2019 | 187 | 0.140 |
Why?
| | United Kingdom | 1 | 2019 | 325 | 0.140 |
Why?
| | Hospital Costs | 2 | 2009 | 123 | 0.140 |
Why?
| | Burnout, Professional | 1 | 2025 | 461 | 0.140 |
Why?
| | Vasoconstriction | 2 | 2023 | 215 | 0.140 |
Why?
| | Random Allocation | 1 | 2018 | 370 | 0.140 |
Why?
| | Nitriles | 1 | 2019 | 192 | 0.140 |
Why?
| | Patient Satisfaction | 1 | 2022 | 697 | 0.140 |
Why?
| | RNA, Bacterial | 1 | 2018 | 189 | 0.130 |
Why?
| | Vancomycin | 1 | 2018 | 92 | 0.130 |
Why?
| | Fat Emulsions, Intravenous | 1 | 1997 | 29 | 0.130 |
Why?
| | Hepatorenal Syndrome | 2 | 2009 | 15 | 0.130 |
Why?
| | Cross-Sectional Studies | 3 | 2020 | 5700 | 0.130 |
Why?
| | Oxygen | 1 | 2023 | 991 | 0.130 |
Why?
| | Pharmacoepidemiology | 2 | 2014 | 22 | 0.130 |
Why?
| | Antibodies, Bacterial | 1 | 2018 | 145 | 0.130 |
Why?
| | Anesthetics, Intravenous | 1 | 1997 | 72 | 0.130 |
Why?
| | Piracetam | 1 | 2017 | 12 | 0.130 |
Why?
| | Critical Care Nursing | 1 | 2018 | 53 | 0.130 |
Why?
| | Sucralfate | 1 | 2017 | 5 | 0.130 |
Why?
| | Immunity, Humoral | 1 | 2018 | 117 | 0.130 |
Why?
| | Cost-Benefit Analysis | 2 | 2014 | 618 | 0.130 |
Why?
| | Drug Compounding | 2 | 2017 | 104 | 0.130 |
Why?
| | Pneumococcal Vaccines | 1 | 2018 | 138 | 0.130 |
Why?
| | Retina | 1 | 2019 | 318 | 0.130 |
Why?
| | Wounds and Injuries | 1 | 2025 | 930 | 0.130 |
Why?
| | Administration, Oral | 5 | 2017 | 835 | 0.120 |
Why?
| | Nitroprusside | 1 | 2016 | 72 | 0.120 |
Why?
| | Thiocyanates | 1 | 2016 | 30 | 0.120 |
Why?
| | Thiosulfates | 1 | 2016 | 19 | 0.120 |
Why?
| | Intracranial Hemorrhages | 1 | 2017 | 99 | 0.120 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2019 | 270 | 0.120 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2018 | 548 | 0.120 |
Why?
| | Analgesics | 1 | 2018 | 231 | 0.120 |
Why?
| | Clinical Trials as Topic | 3 | 2009 | 1037 | 0.120 |
Why?
| | Therapeutics | 1 | 2015 | 14 | 0.110 |
Why?
| | Peptic Ulcer Hemorrhage | 1 | 2014 | 5 | 0.110 |
Why?
| | Placebo Effect | 1 | 2015 | 25 | 0.110 |
Why?
| | Academic Medical Centers | 3 | 2019 | 531 | 0.110 |
Why?
| | beta-Cyclodextrins | 1 | 2015 | 33 | 0.110 |
Why?
| | Mice, Transgenic | 1 | 2020 | 2180 | 0.110 |
Why?
| | Antiviral Agents | 1 | 2021 | 758 | 0.110 |
Why?
| | Methanol | 1 | 2015 | 45 | 0.110 |
Why?
| | Pyridines | 1 | 2019 | 567 | 0.110 |
Why?
| | Respiratory Insufficiency | 1 | 1998 | 325 | 0.110 |
Why?
| | Thrombosis | 1 | 2019 | 399 | 0.110 |
Why?
| | Multivariate Analysis | 3 | 2017 | 1508 | 0.110 |
Why?
| | Vitreoretinopathy, Proliferative | 1 | 2014 | 14 | 0.110 |
Why?
| | Treatment Failure | 2 | 2020 | 357 | 0.110 |
Why?
| | Vasodilator Agents | 1 | 2016 | 330 | 0.110 |
Why?
| | Pain Management | 1 | 2018 | 401 | 0.110 |
Why?
| | Cardiopulmonary Bypass | 1 | 2016 | 217 | 0.110 |
Why?
| | Acute Disease | 3 | 2008 | 1008 | 0.110 |
Why?
| | Practice Guidelines as Topic | 4 | 2015 | 1552 | 0.100 |
Why?
| | Shivering | 1 | 2013 | 5 | 0.100 |
Why?
| | Osmotic Pressure | 1 | 2014 | 34 | 0.100 |
Why?
| | Stress Disorders, Traumatic, Acute | 1 | 2013 | 7 | 0.100 |
Why?
| | Laser Therapy | 1 | 2015 | 130 | 0.100 |
Why?
| | Immunoglobulin G | 1 | 2018 | 893 | 0.100 |
Why?
| | Tomography, Optical Coherence | 3 | 2024 | 260 | 0.100 |
Why?
| | Gene Expression | 1 | 2018 | 1496 | 0.100 |
Why?
| | Pneumonia, Ventilator-Associated | 1 | 2014 | 55 | 0.100 |
Why?
| | Neurologic Examination | 1 | 2013 | 127 | 0.100 |
Why?
| | Genetic Markers | 1 | 2014 | 343 | 0.100 |
Why?
| | Benzodiazepines | 1 | 2014 | 163 | 0.100 |
Why?
| | Drug Storage | 1 | 2013 | 53 | 0.100 |
Why?
| | Medicare | 2 | 2009 | 808 | 0.100 |
Why?
| | Liver Diseases | 1 | 2016 | 304 | 0.100 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2013 | 134 | 0.100 |
Why?
| | Thrombocytopenia | 3 | 2018 | 208 | 0.100 |
Why?
| | Microphthalmos | 1 | 2013 | 2 | 0.100 |
Why?
| | Drug Packaging | 1 | 2013 | 43 | 0.100 |
Why?
| | Hemostasis | 2 | 2019 | 100 | 0.100 |
Why?
| | Drug Stability | 1 | 2013 | 165 | 0.100 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2013 | 178 | 0.100 |
Why?
| | Injections | 1 | 2013 | 193 | 0.100 |
Why?
| | Health Care Surveys | 1 | 2014 | 562 | 0.090 |
Why?
| | Lens Implantation, Intraocular | 1 | 2013 | 67 | 0.090 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 2 | 2023 | 255 | 0.090 |
Why?
| | Propensity Score | 1 | 2014 | 343 | 0.090 |
Why?
| | Motilin | 1 | 2011 | 1 | 0.090 |
Why?
| | Cholecystokinin | 1 | 2011 | 15 | 0.090 |
Why?
| | Models, Genetic | 1 | 2014 | 587 | 0.090 |
Why?
| | Respiratory Aspiration | 1 | 2011 | 32 | 0.090 |
Why?
| | Phacoemulsification | 1 | 2013 | 120 | 0.090 |
Why?
| | RNA, Messenger | 1 | 2018 | 2828 | 0.080 |
Why?
| | Societies, Pharmaceutical | 2 | 2020 | 21 | 0.080 |
Why?
| | Animals | 5 | 2020 | 37697 | 0.080 |
Why?
| | Renal Dialysis | 1 | 2015 | 460 | 0.080 |
Why?
| | Intraoperative Complications | 2 | 2013 | 150 | 0.080 |
Why?
| | Drug Administration Schedule | 4 | 2018 | 772 | 0.080 |
Why?
| | Drug Resistance, Multiple | 1 | 2010 | 25 | 0.080 |
Why?
| | Adolescent | 8 | 2019 | 22326 | 0.080 |
Why?
| | Lactoferrin | 1 | 2010 | 38 | 0.080 |
Why?
| | Contraindications | 1 | 2010 | 86 | 0.080 |
Why?
| | Hospitals, University | 2 | 2008 | 176 | 0.080 |
Why?
| | Severity of Illness Index | 2 | 2015 | 2927 | 0.080 |
Why?
| | Mice, Inbred C57BL | 2 | 2018 | 5967 | 0.080 |
Why?
| | Imipenem | 2 | 2010 | 15 | 0.070 |
Why?
| | Multiple Organ Failure | 1 | 2010 | 127 | 0.070 |
Why?
| | Databases, Factual | 2 | 2018 | 1458 | 0.070 |
Why?
| | Observer Variation | 1 | 2010 | 358 | 0.070 |
Why?
| | Kidney Failure, Chronic | 1 | 2015 | 600 | 0.070 |
Why?
| | Hypoglycemia | 1 | 2013 | 473 | 0.070 |
Why?
| | Diagnostic Errors | 1 | 2010 | 176 | 0.070 |
Why?
| | Follow-Up Studies | 4 | 2024 | 5270 | 0.070 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2010 | 144 | 0.070 |
Why?
| | Risk Assessment | 2 | 2014 | 3562 | 0.070 |
Why?
| | Patient Care Team | 1 | 2013 | 682 | 0.070 |
Why?
| | Pilot Projects | 1 | 2013 | 1829 | 0.070 |
Why?
| | Data Interpretation, Statistical | 1 | 2010 | 374 | 0.070 |
Why?
| | Quality Improvement | 3 | 2020 | 1255 | 0.070 |
Why?
| | Vitamin K | 1 | 2007 | 47 | 0.070 |
Why?
| | Blood Pressure | 2 | 2004 | 1745 | 0.070 |
Why?
| | Gene Expression Profiling | 1 | 2014 | 1773 | 0.060 |
Why?
| | Databases as Topic | 1 | 2007 | 68 | 0.060 |
Why?
| | Magnesium | 1 | 2007 | 156 | 0.060 |
Why?
| | Phosphorus | 1 | 2007 | 99 | 0.060 |
Why?
| | Potassium | 1 | 2007 | 148 | 0.060 |
Why?
| | Cost Control | 1 | 2006 | 37 | 0.060 |
Why?
| | Cellulitis | 1 | 2007 | 55 | 0.060 |
Why?
| | Burn Units | 1 | 2007 | 48 | 0.060 |
Why?
| | Biomarkers | 2 | 2015 | 4207 | 0.060 |
Why?
| | Cerebral Hemorrhage | 1 | 2007 | 118 | 0.060 |
Why?
| | Canada | 2 | 2014 | 428 | 0.060 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2011 | 1225 | 0.060 |
Why?
| | Antihypertensive Agents | 1 | 2010 | 511 | 0.060 |
Why?
| | Anxiety | 1 | 2013 | 1087 | 0.060 |
Why?
| | Societies, Medical | 2 | 2020 | 866 | 0.060 |
Why?
| | Reproducibility of Results | 2 | 2014 | 3362 | 0.060 |
Why?
| | Economics, Pharmaceutical | 1 | 2005 | 10 | 0.060 |
Why?
| | Pipecolic Acids | 1 | 2005 | 26 | 0.060 |
Why?
| | Fibrinolysis | 1 | 2007 | 162 | 0.060 |
Why?
| | Kidney Diseases | 1 | 2009 | 412 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 1 | 2014 | 2388 | 0.060 |
Why?
| | Arginine Vasopressin | 1 | 2005 | 43 | 0.060 |
Why?
| | Octreotide | 1 | 2005 | 26 | 0.060 |
Why?
| | Time and Motion Studies | 1 | 2025 | 26 | 0.060 |
Why?
| | Ranibizumab | 1 | 2024 | 20 | 0.060 |
Why?
| | Quality-Adjusted Life Years | 1 | 2005 | 112 | 0.060 |
Why?
| | Costs and Cost Analysis | 1 | 2005 | 220 | 0.050 |
Why?
| | Blood Component Transfusion | 1 | 2005 | 100 | 0.050 |
Why?
| | Ceftazidime | 1 | 2004 | 6 | 0.050 |
Why?
| | beta-Lactam Resistance | 1 | 2004 | 9 | 0.050 |
Why?
| | Case-Control Studies | 2 | 2014 | 3604 | 0.050 |
Why?
| | Mice | 2 | 2020 | 18172 | 0.050 |
Why?
| | Intraocular Pressure | 2 | 2019 | 316 | 0.050 |
Why?
| | Ciprofloxacin | 1 | 2004 | 26 | 0.050 |
Why?
| | Tobramycin | 1 | 2004 | 52 | 0.050 |
Why?
| | Drug Substitution | 1 | 2024 | 62 | 0.050 |
Why?
| | Sentinel Surveillance | 1 | 2004 | 48 | 0.050 |
Why?
| | Urine | 1 | 2004 | 62 | 0.050 |
Why?
| | Bevacizumab | 1 | 2024 | 135 | 0.050 |
Why?
| | Depression | 1 | 2013 | 1503 | 0.050 |
Why?
| | Wet Macular Degeneration | 1 | 2024 | 58 | 0.050 |
Why?
| | Hospitals, Teaching | 1 | 2004 | 115 | 0.050 |
Why?
| | Hospitals, Urban | 1 | 2004 | 137 | 0.050 |
Why?
| | Sex Factors | 1 | 2009 | 2074 | 0.050 |
Why?
| | Neoplasms | 1 | 2018 | 2761 | 0.050 |
Why?
| | Models, Biological | 1 | 2010 | 1821 | 0.050 |
Why?
| | Skin Diseases | 1 | 2004 | 148 | 0.050 |
Why?
| | Adrenal Cortex | 1 | 2002 | 33 | 0.050 |
Why?
| | Consensus | 1 | 2025 | 546 | 0.050 |
Why?
| | Liver Transplantation | 1 | 2009 | 811 | 0.050 |
Why?
| | Hospital Mortality | 1 | 2007 | 952 | 0.050 |
Why?
| | Age Factors | 1 | 2009 | 3316 | 0.050 |
Why?
| | Pneumonia, Bacterial | 1 | 2003 | 116 | 0.050 |
Why?
| | Chronic Disease | 2 | 2020 | 1815 | 0.040 |
Why?
| | Hypertension | 1 | 2010 | 1257 | 0.040 |
Why?
| | Hospitals | 1 | 2006 | 690 | 0.040 |
Why?
| | Gastric Mucosa | 1 | 2000 | 53 | 0.040 |
Why?
| | Gastrointestinal Motility | 1 | 2000 | 29 | 0.040 |
Why?
| | Young Adult | 4 | 2019 | 13878 | 0.040 |
Why?
| | Subretinal Fluid | 1 | 2020 | 1 | 0.040 |
Why?
| | Stomach | 1 | 2000 | 114 | 0.040 |
Why?
| | Lasers, Semiconductor | 1 | 2020 | 12 | 0.040 |
Why?
| | Therapeutic Index | 1 | 2020 | 3 | 0.040 |
Why?
| | Methadone | 1 | 2001 | 109 | 0.040 |
Why?
| | Indocyanine Green | 1 | 2020 | 42 | 0.040 |
Why?
| | Heart Rate | 1 | 2004 | 840 | 0.040 |
Why?
| | Sickness Impact Profile | 1 | 2020 | 59 | 0.040 |
Why?
| | Quality of Health Care | 1 | 2025 | 649 | 0.040 |
Why?
| | Coloring Agents | 1 | 2020 | 96 | 0.040 |
Why?
| | Cost Savings | 1 | 2000 | 86 | 0.040 |
Why?
| | Electroretinography | 1 | 2019 | 51 | 0.040 |
Why?
| | Chi-Square Distribution | 1 | 2001 | 527 | 0.040 |
Why?
| | Placebos | 1 | 2000 | 195 | 0.040 |
Why?
| | Intestinal Absorption | 1 | 2000 | 93 | 0.040 |
Why?
| | Fluorescein Angiography | 1 | 2020 | 176 | 0.040 |
Why?
| | Causality | 1 | 2019 | 132 | 0.040 |
Why?
| | Linear Models | 1 | 2001 | 857 | 0.040 |
Why?
| | Nausea | 1 | 1998 | 112 | 0.030 |
Why?
| | Data Collection | 1 | 2001 | 655 | 0.030 |
Why?
| | Equipment Design | 1 | 2019 | 530 | 0.030 |
Why?
| | Child | 2 | 2017 | 22562 | 0.030 |
Why?
| | Vomiting | 1 | 1998 | 129 | 0.030 |
Why?
| | Parenteral Nutrition, Total | 1 | 1997 | 27 | 0.030 |
Why?
| | Comparative Effectiveness Research | 1 | 2018 | 164 | 0.030 |
Why?
| | Administration, Intravenous | 1 | 2017 | 172 | 0.030 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2019 | 240 | 0.030 |
Why?
| | Netherlands | 1 | 2015 | 86 | 0.030 |
Why?
| | Quality of Life | 2 | 2020 | 3064 | 0.030 |
Why?
| | Vision, Ocular | 1 | 2015 | 46 | 0.030 |
Why?
| | Emergency Service, Hospital | 1 | 2007 | 2251 | 0.030 |
Why?
| | Diagnostic Techniques, Ophthalmological | 1 | 2015 | 50 | 0.030 |
Why?
| | Standard of Care | 1 | 2014 | 77 | 0.030 |
Why?
| | Eye Proteins | 1 | 2014 | 92 | 0.030 |
Why?
| | Clinical Protocols | 1 | 2015 | 274 | 0.030 |
Why?
| | Acidosis | 1 | 2015 | 104 | 0.030 |
Why?
| | Crohn Disease | 1 | 1997 | 256 | 0.030 |
Why?
| | Retinal Detachment | 1 | 2014 | 75 | 0.030 |
Why?
| | Seizures | 1 | 2017 | 452 | 0.020 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2014 | 385 | 0.020 |
Why?
| | Axial Length, Eye | 1 | 2013 | 16 | 0.020 |
Why?
| | Rats | 1 | 2001 | 5585 | 0.020 |
Why?
| | Tonometry, Ocular | 1 | 2013 | 103 | 0.020 |
Why?
| | ROC Curve | 1 | 2014 | 600 | 0.020 |
Why?
| | Logistic Models | 1 | 2017 | 2102 | 0.020 |
Why?
| | Risk | 1 | 2014 | 905 | 0.020 |
Why?
| | Recovery of Function | 1 | 2015 | 697 | 0.020 |
Why?
| | Genes, Regulator | 1 | 2010 | 36 | 0.020 |
Why?
| | Antithrombins | 1 | 2010 | 69 | 0.020 |
Why?
| | Odds Ratio | 1 | 2013 | 1057 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2010 | 333 | 0.020 |
Why?
| | Microcirculation | 1 | 2010 | 137 | 0.020 |
Why?
| | Genotype | 1 | 2014 | 1866 | 0.020 |
Why?
| | Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2009 | 38 | 0.020 |
Why?
| | Research Design | 1 | 2015 | 1113 | 0.020 |
Why?
| | Drug Utilization | 1 | 2008 | 166 | 0.020 |
Why?
| | Liver Cirrhosis | 1 | 2009 | 285 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2010 | 1267 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 1997 | 2771 | 0.020 |
Why?
| | Drug Costs | 1 | 2008 | 114 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2014 | 2146 | 0.020 |
Why?
| | Inpatients | 1 | 2010 | 517 | 0.010 |
Why?
| | Thienamycins | 1 | 2005 | 3 | 0.010 |
Why?
| | Polymyxin B | 1 | 2005 | 20 | 0.010 |
Why?
| | Colistin | 1 | 2005 | 10 | 0.010 |
Why?
| | Antidiuretic Agents | 1 | 2005 | 5 | 0.010 |
Why?
| | Platelet Activation | 1 | 2005 | 94 | 0.010 |
Why?
| | Platelet Aggregation | 1 | 2005 | 102 | 0.010 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2004 | 68 | 0.010 |
Why?
| | Arginine | 1 | 2005 | 259 | 0.010 |
Why?
| | Hospitalization | 1 | 2014 | 2293 | 0.010 |
Why?
| | Endothelial Cells | 1 | 2010 | 832 | 0.010 |
Why?
| | Guideline Adherence | 1 | 2008 | 565 | 0.010 |
Why?
| | DNA | 1 | 2010 | 1447 | 0.010 |
Why?
| | Drug Resistance, Microbial | 1 | 2003 | 67 | 0.010 |
Why?
| | Kidney Transplantation | 1 | 2009 | 695 | 0.010 |
Why?
| | Algorithms | 1 | 2010 | 1791 | 0.010 |
Why?
| | Transcription Factors | 1 | 2010 | 1728 | 0.010 |
Why?
| | Cardiac Surgical Procedures | 1 | 2008 | 588 | 0.010 |
Why?
| | Sulfonamides | 1 | 2005 | 579 | 0.010 |
Why?
| | Liver | 1 | 2010 | 1848 | 0.010 |
Why?
| | Population Surveillance | 1 | 2004 | 485 | 0.010 |
Why?
| | Postoperative Complications | 1 | 2013 | 2862 | 0.010 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2001 | 277 | 0.010 |
Why?
|
|
MacLaren's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|